PittPharmacy PhD candidate Jieni Xu  gave a podium presentation on her project “Pendent HDAC inhibitor SAHA derivatized polymer as a novel prodrug micellar carrier for anticancer drugs” at the  255th American Chemical Society (ACS) national meeting in New Orleans, Louisiana, March 2018. This national meeting attracts more than 12,000 worldwide chemists and pharmaceutical professionals from the academia, government, and industry, aiming for promoting new multidisciplinary research by sharing the latest information in their areas of professional interest.

Xu has successfully developed a pro-drug nanoparticle to co-deliver HDAC inhibitor SAHA, a FDA approved anti-cancer drug, and another chemotherapeutic agent doxorubicin (DOX). This novel developed nanoparticle showed significant synergistic effect of SAHA and DOX with enhanced efficacy and decreased toxicity of single agent, which thereby opens new avenues for combinational strategies in future anticancer therapy. Detailed information about this project, please see: https://www.tandfonline.com/doi/abs/10.1080/1061186X.2017.1419355.”

Professor Song Li, MD, PhD is Xu’s faculty advisor.


Leave a comment